Latuda lurasidone: Phase III data

The double-blind, international Phase III RESOLVE 1 trial in 211 MDD patients who presented with a limited number of manic symptoms showed that flexibly-dosed, once-daily 20-60 mg Latuda met

Read the full 294 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE